Vitamin E linked to increased risk of heart failure

Key points
- The original HOPE (Heart Outcomes Prevention Evaluation) trial found no evidence that vitamin E affects the outcome of Heart disease after 4.5 years.
- Thinking that the treatment period may have been too short to show a benefit, Dr.
- There were no significant differences between the vitamin E group and the placebo group in cancer rate, cancer deaths, major cardiovascular events (heart attack, stroke, or death from cardiovascular causes), or death from any cause in the extension study.
- However, the risk of heart failure was higher in the vitamin E group than in the placebo group (14.7 percent versus 12.6 percent), as was the risk of hospitalization for heart failure (5.8 percent versus 4.2 percent).
The results of a seven-year study examining the potential benefit of vitamin E in preventing cancer and cardiovascular events in older patients with vascular disease or Diabetes not only showed no benefit from taking the supplement, it showed an increased risk of heart failure, according to a report in the Journal of the American Medical Association.
The original HOPE (Heart Outcomes Prevention Evaluation) trial found no evidence that vitamin E affects the outcome of Heart disease after 4.5 years. The study included approximately 9,500 patients, 55 years of age or older, with vascular disease or diabetes assigned to a placebo or 400 IU per day of vitamin E.
Thinking that the treatment period may have been too short to show a benefit, Dr. Eva Lonn, at McMaster University in Hamilton, Ontario, and colleagues, extended the HOPE study for 2.5 more years. In HOPE-The Ongoing Outcomes (HOPE-TOO) trial, nearly 4,000 subjects continued in the trial.
There were no significant differences between the vitamin E group and the placebo group in cancer rate, cancer deaths, major cardiovascular events (heart attack, stroke, or death from cardiovascular causes), or death from any cause in the extension study.
However, the risk of heart failure was higher in the vitamin E group than in the placebo group (14.7 percent versus 12.6 percent), as was the risk of hospitalization for heart failure (5.8 percent versus 4.2 percent).
"In conjunction with its lack of efficacy, the potential for harm suggested by our findings strongly supports the view that vitamin E supplements should not be used in patients with vascular disease or diabetes mellitus," Lonn's group advises.
"HOPE-TOO reemphasizes the importance of controlled clinical trials for testing important hypotheses deriving from basic biological findings or from epidemiological observations," Dr. B. Greg Brown and Dr. John Crowley, at the University of Washington in Seattle, write in an accompanying editorial.
SOURCE: Journal of the American Medical Association, March 16, 2005.
Written and revised by
David Cohen, M.D.
Our doctors write and review articles for accuracy and keep them up to date.
health.am provides general information, not medical advice. Always consult a qualified health professional about your own health.
Explore health topics
More in this topic
Heart & Blood Vessels →
NewsBlood transfusion associated with increased risk of death for patients with heart attack
A meta-analysis of 10 studies suggests that receipt of a blood transfusion among patients with myocardial infarction (heart attack) was associated with increased all-cause mortality compared with not receiving a blood…
25 December 2012
NewsOmega-6 fats not linked to heart failure risk
Despite evidence suggesting omega-6 fatty acids might protect the cardiovascular system, a large new study of men finds the fats typically found in flax seeds and some vegetable oils do nothing to prevent heart failure.…
7 December 2012
NewsStudy suggests stem cell transplant survivors at increased risk of developing heart disease
New research appearing online today in Blood, the Journal of the American Society of Hematology (ASH), suggests that long-term survivors of hematopoietic cell transplants (HCT) are at an increased risk of developing…



